Hybrid Coronary Revascularization for the Treatment of Left Main Coronary Artery Disease in High-Risk Patients
Objective: Hybrid coronary revascularization is an alter-native for treatment for high-risk patients with coronary artery disease. We evaluated the efficacy of staged hybrid coronary revascularization for the treatment of unprotected left main coronary artery disease in high-risk patients.
Methods: Patients with left main or proximal left anterior descending coronary artery stenosis who are not good can-didates for percutaneous coronary intervention and who had suitable lesions in the right coronary and circumflex arteries were considered for staged hybrid therapy if they had poor left ventricular functions (ejection fraction <0.40) and comor-bid illnesses. From January 2008 through December 2010,Â 11 patients (8 men, 3 women; mean age: 66.1 Â± 9.1 years) were treated with off-pump coronary artery bypass grafting com-bined with staged percutaneous coronary intervention. Nine patients had left main coronary artery stenosis together with circumflex or right coronary artery stenosis, and 2 patients had proximal left anterior descending artery stenosis and right coronary artery stenosis.
Results: After off-pump coronary artery bypass grafting, procedure-related complications did not occur, and there was no in-hospital death. Coronary re-angiography after a median of 16 days revealed patent and functioning left inter-nal mammarian artery grafts in all patients. Applying subse-quent percutaneous transluminal coronary angioplasty and occasional stenting (n = 14), a total of 14 lesions were treated successfully. Procedure related complications did not occur. All patients remained angina-free, and no stress electrocar-diographic changes were recorded.
Conclusion: Our preliminary results indicate that a “staged hybrid” approach to the treatment of left main coro-nary artery disease in high-risk patients is safe and effective. Hybrid coronary revascularization enables complete revascu-larization and may be an alternative method of treating left main coronary artery disease in selected high-risk patients.
Bonatti J, Lehr E, Vesely MR, Friedrich G, Bonaros N, Zimrin D. 2010. Hybrid coronary revascularization: which patients? When? How? Curr Opin Cardiol 25:568-74.nCisowski M, Morawski W, Drzewiecki J, et al. 2002. Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization. Eur J Cardiothorac Surg 22:261-5.nDavidavicius G, Van Praet F, Mansour S, et al. 2005. Hybrid revascularization strategy: a pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention. Circulation 112:I317-22.nDel Giglio M, Dell'Amore A, Zuffi A, Sokoli A. 2009. One-stage hybrid procedure: association between awake minimally invasive surgical revascularization and percutaneous coronary intervention. Interact Cardiovasc Thorac Surg 9:551-3.nGao C, Yang M, Wu Y, et al. 2009. Hybrid coronary revascularization by endoscopic robotic coronary artery bypass grafting on beating heart and stent placement. Ann Thorac Surg 87:737-41.nHolzhey DM, Jacobs S, Mochalski M, et al. 2008. Minimally invasive hybrid coronary artery revascularization. Ann Thorac Surg 86:1856-60.nHulusi M, Basaran M, Ugurlucan M, Kocailik A, Basaran EK. 2009. Coronary artery bypass grafting with Y-saphenous vein grafts. Angiology 60:668-75.nJones ML, Qiu S, Sudarshan C. 2010. Perioperative outcomes in hybrid versus conventional surgical coronary artery revascularisation. Interact Cardiovasc Thorac Surg 11:292-6.nMurphy GJ, Bryan AJ, Angelini GD. 2004. Hybrid coronary revascularization in the era of drug-eluting stents. Ann Thorac Surg 78:1861-7.nReicher B, Poston RS, Mehra MR, et al. 2008. Simultaneous "hybrid" percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes. Am Heart J 155:661-7.nUs MH, Basaran M, Yilmaz M, et al. 2006. Hybrid coronary revascularization in high-risk patients. Tex Heart Inst J 33:458-62.nVassiliades TA Jr, Douglas JS, Morris DC, et al. 2006. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. J Thorac Cardiovasc Surg 131:956-62.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).